AbbVie (0QCV) Stock Overview
A research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 2/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
0QCV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$249.92 |
| 52 Week High | US$273.25 |
| 52 Week Low | US$186.49 |
| Beta | 0.28 |
| 1 Month Change | 0.11% |
| 3 Month Change | 9.99% |
| 1 Year Change | 13.50% |
| 3 Year Change | 62.76% |
| 5 Year Change | 131.79% |
| Change since IPO | 923.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0QCV | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -4.3% | -0.08% | -0.7% |
| 1Y | 13.5% | -23.3% | 16.1% |
Return vs Industry: 0QCV exceeded the UK Biotechs industry which returned -23.3% over the past year.
Return vs Market: 0QCV underperformed the UK Market which returned 16.1% over the past year.
Price Volatility
| 0QCV volatility | |
|---|---|
| 0QCV Average Weekly Movement | 3.8% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QCV has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0QCV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions.
AbbVie Inc. Fundamentals Summary
| 0QCV fundamental statistics | |
|---|---|
| Market cap | US$443.39b |
| Earnings (TTM) | US$6.27b |
| Revenue (TTM) | US$64.39b |
Is 0QCV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0QCV income statement (TTM) | |
|---|---|
| Revenue | US$64.39b |
| Cost of Revenue | US$17.52b |
| Gross Profit | US$46.87b |
| Other Expenses | US$40.60b |
| Earnings | US$6.27b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.55 |
| Gross Margin | 72.79% |
| Net Profit Margin | 9.74% |
| Debt/Equity Ratio | -1,203.9% |
How did 0QCV perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/10 07:55 |
| End of Day Share Price | 2026/09/09 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AbbVie Inc. is covered by 51 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |